13F filer · CIK 1816307
SILVERARC CAPITAL MANAGEMENT, LLC
BOSTON, MA · filing since Q4 2020 · last filing Aug 13, 2026
Reported value
$962.2M
$-17.7M vs prior
Positions
73
New / sold out
26 / 26
Added / reduced
17 / 27
Turnover
36.4%
buys $353.3M · sells $500.3M
Top-10 weight
42.3%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | ASCENDIS PHARMA A/S | +206,234 | – | +$55.0M |
| New | ENLIVEN THERAPEUTICS INC | +489,382 | – | +$24.8M |
| New | SAGIMET BIOSCIENCES INC | +2,927,698 | – | +$22.6M |
| New | ARK ETF TRPUT | +500,000 | – | +$21.0M |
| Added | ORUKA THERAPEUTICS INC | +201,894 | +133.8% | +$19.2M |
| New | DEFINIUM THERAPEUTICS INC | +400,000 | – | +$18.8M |
| Added | CELCUITY INC | +143,093 | +40.0% | +$15.0M |
| New | ALX ONCOLOGY HLDGS INC | +5,744,757 | – | +$11.9M |
| New | VERADERMICS INC | +95,000 | – | +$11.7M |
| New | AVALYN PHARMACEUTICALS INC | +330,487 | – | +$10.9M |
33 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | SPDR SERIES TRUSTPUT | -825,000 | -100.0% | $-105.4M |
| Sold out | KALVISTA PHARMACEUTICALS INC | -2,876,407 | -100.0% | $-57.9M |
| Sold out | NUVALENT INC | -354,914 | -100.0% | $-36.4M |
| Sold out | ASCENDIS PHARMA A/S | -124,658 | -100.0% | $-28.5M |
| Reduced | DIANTHUS THERAPEUTICS INC | -264,746 | -40.4% | $-25.8M |
| Reduced | MONTE ROSA THERAPEUTICS INC | -893,745 | -44.6% | $-21.6M |
| Sold out | CENTESSA PHARMACEUTICALS PLC | -466,345 | -100.0% | $-18.5M |
| Reduced | ALKERMES PLC | -346,820 | -75.3% | $-18.2M |
| Reduced | ABIVAX SA | -132,937 | -43.9% | $-17.7M |
| Reduced | KODIAK SCIENCES INC | -445,674 | -44.9% | $-17.4M |
43 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | ASCENDIS PHARMA A/SORD SHS | 206,234 | $55.0M | 5.72% |
| 2 | CELCUITY INCCOM | 500,996 | $52.4M | 5.45% |
| 3 | COGENT BIOSCIENCES INCCOM | 1,280,707 | $49.6M | 5.15% |
| 4 | UROGEN PHARMA LTDCOM | 1,301,979 | $47.9M | 4.98% |
| 5 | IMMUNOME INCCOM | 2,017,009 | $42.7M | 4.44% |
| 6 | DIANTHUS THERAPEUTICS INCCOM | 390,000 | $38.0M | 3.95% |
| 7 | RHYTHM PHARMACEUTICALS INCCOM | 311,461 | $34.6M | 3.59% |
| 8 | ORUKA THERAPEUTICS INCCOM | 352,802 | $33.6M | 3.49% |
| 9 | MONTE ROSA THERAPEUTICS INCCOM | 1,108,295 | $26.8M | 2.79% |
| 10 | SYNDAX PHARMACEUTICALS INCCOM | 1,214,390 | $26.5M | 2.76% |
63 more rows. Subscribe for $29/month to see every row, download the data and use the API.